Experimental HIV Vaccine Regimen Is Well-Tolerated, Elicits Immune Responses

Article, News & Updates |

Source: hiv.gov

Results From Early-Stage NIH-Funded Trial Support Further Development of Candidate Vaccines

Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate vaccine safety and efficacy among women at risk of acquiring HIV.

Click Here To Read More